FDA's Stepwise Approach To Demonstrating Biosimilarity
On Feb. 9, the U.S. Food and Drug Administration issued the agency's first set of draft guidance documents outlining the framework for how it will evaluate applications for regulatory approval of...To view the full article, register now.
Already a subscriber? Click here to view full article